Airgas Therapeutics, LLC appears in FDA premarket notification records as the applicant for the ULSPIRA TS™ Nitric Oxide Therapy System, filed under regulation number 21 CFR 868.5165 for a nitric oxide administration apparatus in Class II. The linked FDA records identify product code MRN and an anesthesiology review panel. The company's documented activity in these records is 510(k) submission work for that device family, with decision dates spanning 2023 through 2026. [1][3][5][8]
Documented device identity and classification
FDA records describe the ULSPIRA TS™ Nitric Oxide Therapy System as a nitric oxide administration apparatus under 21 CFR 868.5165, Class II, with product code MRN and anesthesiology as the medical specialty and review panel. The device name in the openFDA fields is listed as apparatus for nitric oxide delivery. The applicant of record is Airgas Therapeutics, LLC. [1][3][5]
The K253095 record lists a Traditional clearance type, no third-party review, and a summary statement. The decision code is SESE, described as Substantially Equivalent, with a decision date of October 30, 2026, and a date received of September 23, 2025. [1]
Filing history in the linked records
An earlier 510(k), K212409, was received August 3, 2021, and decided June 30, 2023, as Substantially Equivalent, Traditional, not reviewed by a third party, and not a combination product. The FDA letter for that filing is addressed to Airgas Therapeutics at a Houston, Texas correspondence address and names the same trade device and regulation number. [5][8]
A later filing, K242374, carries a January 17, 2025 FDA letter addressed to Airgas Therapeutics LLC care of a named president at a Tampa, Florida correspondence address. That letter lists the same trade name, regulation number 21 CFR 868.5165, Class II, and product codes MRN, MRO, MRP, MRQ and CCL. [3]
The most recent linked record, K253095, was decided October 30, 2026. The linked collection contains one 510(k) record in its sample and one SESE decision in both the full decision counts and the sample decision counts; these figures describe the linked records at the retrieval date, not company-wide totals. [1]
Published system documentation
Airgas Therapeutics' published brochure describes the ULSPIRA™ Solution as a nitric oxide delivery system intended for use in the NICU setting, and the Airgas product page presents ULSPIRA nitric oxide gas for inhalation alongside the ULSPIRA Solution machine. These descriptions come from the manufacturer's published materials, not from FDA review documents. [4][7]
The manufacturer's product page lists handling notes for the ULSPIRA TS system, including a pre-use check, use of a backup system if an unintended treatment interruption occurs, and a statement that the system must not be used in an MRI environment. The page marks the product Rx Only and provides customer service and clinical/technical support telephone numbers. [4]
Applicant identity and open questions
The FDA records identify Airgas Therapeutics, LLC as the legal applicant and give correspondence addresses in Houston, Texas and Tampa, Florida across different filings; these are filing addresses, not verified headquarters. The Airgas product page carries Airgas branding described as an Air Liquide company, while the FDA filings name Airgas Therapeutics, LLC as applicant. The precise corporate relationship between the applicant and that brand is not established by the linked records. [1][3][4][5]
The linked records do not document sales volumes, market share, customer lists, certifications, or independent clinical performance results for the ULSPIRA TS system. Details beyond the filing scope, device classification and published product descriptions remain unknown from these sources. [1][3][7]
